Decreased disappearance rate of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) from the blood and its unresponsiveness to tocophreyl nicotinate and indomethacin in patients with primary hepatocellular carcinoma.
The disappearance rates(K) of FT-207 from the blood in patients with primary hepatoma and advanced cirrhosis of the liver were significantly lower than those in control patients with cancer but normal liver function. Pretreatment with tocopheryl nicotinate and indomethacin increased the K values in the control subjects, but was without effect on the K values in patients with primary hepatoma.
D006528:Carcinoma, Hepatocellular / Q000097:blood* / Q000150:complications; D005472:Fluorouracil / Q000031:analogs & derivatives*; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology*; D007700:Kinetics; D008103:Liver Cirrhosis / Q000097:blood / Q000150:complications; D008113:Liver Neoplasms / Q000097:blood* / Q000150:complications; D008862:Microsomes, Liver / Q000201:enzymology; D009539:Nicotinic Acids; D005641:Tegafur / Q000097:blood*; D014810:Vitamin E / Q000031:analogs & derivatives
D009539:Nicotinic Acids; D014810:Vitamin E; D005641:Tegafur; C012581:alpha-tocopheryl nicotinate; D005472:Fluorouracil; D007213:Indomethacin